Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

ProstaLund

Less than 1K followers
Overview
Investor consensus
All
Press releases
3rd party
ShowingAll content types
Regulatory press release10/24/2025, 5:30 AM

PROSTALUND AB (publ) - Interim report January-September 2025

ProstaLund
Press release9/12/2025, 6:00 AM

ProstaLund enters collaboration agreement with the XEN Group for the market in the United Arab Emirates and Oman

ProstaLund
Press release9/10/2025, 6:00 AM

ProstaLund enters collaboration agreement with Mayumana Healthcare for the Benelux market

ProstaLund

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release8/21/2025, 5:30 AM

ProstaLund AB - Interim Report January-June 2025

ProstaLund
Press release6/26/2025, 2:45 PM

First CoreTherm® Eagle treatments performed in Denmark

ProstaLund
Press release6/17/2025, 8:00 AM

Second clinic in Sweden starts treatment with CoreTherm® Eagle

ProstaLund
Regulatory press release5/30/2025, 5:30 AM

ProstaLund AB - Interim report January-March 2025

ProstaLund
Press release5/20/2025, 1:50 PM

First patients treated with CoreTherm® Eagle

ProstaLund
Press release5/14/2025, 8:45 AM

First treatments with CoreTherm® Eagle to be performed next week – Key milestone for ProstaLund

ProstaLund
Press release2/24/2025, 2:00 PM

Correction: Use of the Schelin Catheter® prior to water vapor thermal therapy shown to be cost-effective

ProstaLund
Press release2/24/2025, 8:05 AM

Use of the Schelin Catheter® prior to water vapor thermal therapy shown to be cost-effective

ProstaLund
Regulatory press release2/20/2025, 6:30 AM

ProstaLund AB - Year-end report 2024

ProstaLund
Press release2/14/2025, 2:45 PM

New study confirms the strong efficacy of CoreTherm® in patients with large prostates

ProstaLund
Press release1/27/2025, 9:00 AM

Elderly men treated with CoreTherm® for benign prostatic hyperplasia have lower risk for a prostate cancer diagnosis later in life compared to men treated with TURP, according to a new Swedish register study

ProstaLund
Press release12/10/2024, 8:00 AM

Additional study published confirming effectiveness of transurethral intraprostatic anaesthesia (TUIA) using our Schelin Catheter® during benign prostatic enlargement treatments

ProstaLund
Third party research11/11/2024, 12:11 PM

ProstaLund: CoreTherm Eagle flygfärdig - VH Corp

* Tio CoreTherm Eagle-maskiner är tillverkade * Förbättrat patientflöde jämfört med första halvåret * Vi behåller vårt motiverade värde om 0,81 SEK per aktie ProstaLunds nettoomsättning i Q3 om 3,5 MSEK var klart lägre jämfört med samma period 2023. ...

ProstaLund
Press release11/7/2024, 11:00 AM

The first ten CoreTherm® Eagle machines are manufactured

ProstaLund
Regulatory press release11/7/2024, 6:30 AM

Interim report January-September 2024

ProstaLund
Press release10/11/2024, 8:00 AM

Short-term results and long-term durability after CoreTherm® treatments presented at the Emirates International Urological Conference in Dubai, UAE

ProstaLund
Press release10/4/2024, 11:00 AM

First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate

ProstaLund
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.